From Seekingalpha · Terry Chrisomalis · · 50s
Cartesian Therapeutics Maintains 'Buy' Rating
Cartesian Therapeutics keeps 'Buy' rating with Descartes-08 cell therapy progress and CAR-T agreement.
In brief
Cartesian Therapeutics keeps 'Buy' rating with Descartes-08 cell therapy progress and CAR-T agreement. Cartesian Therapeutics maintains 'Buy' rating due to Descartes-08 cell therapy advancements and CAR-T agreement. Originally reported by Seekingalpha.
Rating Update
Cartesian Therapeutics maintains a 'Buy' rating driven by advancing Descartes-08 cell therapy programs and late-stage clinical catalysts.
Clinical Timeline
Topline results from phase 3 AURORA study in AChR Ab+ Myasthenia Gravis expected in Q1 2027 with potential BLA filing in mid-2027.
Strategic Expansion
RNAC expands Descartes-08 into myositis indications and pursues in vivo CAR-T approach via WestGene licensing agreement with initial data in H1 2027.
Financial Position
Strong cash position of $149.3M as of June 2026 provides operational runway into 2028 for clinical and strategic initiatives.
What it means
Cartesian Therapeutics maintains 'Buy' rating due to Descartes-08 cell therapy advancements and CAR-T agreement.
